These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 16607805

  • 1. [Susceptibility to norfloxacin of some bacterial strains causing urinary infections].
    Tuchiluş C, Poiată A, Bădicuţ I, Buiuc D.
    Rev Med Chir Soc Med Nat Iasi; 2005; 109(2):383-6. PubMed ID: 16607805
    [Abstract] [Full Text] [Related]

  • 2. In vitro activity of pefloxacin compared with five other quinolones on nalidixic acid-resistant proteae species.
    Piccolomini R, Cellini L, Allocati N, Di Girolamo A, Selan L, Scazzocchio F.
    Chemioterapia; 1988 Oct; 7(5):287-91. PubMed ID: 3224396
    [Abstract] [Full Text] [Related]

  • 3. The frequency of in vitro resistance to fluoroquinolones among clinical isolates of Escherichia coli.
    Poiată A, Bădicuţ I, Grigore L, Buiuc D.
    Roum Arch Microbiol Immunol; 2000 Oct; 59(1-2):63-9. PubMed ID: 11845477
    [Abstract] [Full Text] [Related]

  • 4. [In vitro determination of the sensitivity of mycobacteria to fluoroquinolones].
    Dailloux M, Petitpain N, Henry C, Weber M.
    Pathol Biol (Paris); 1989 May; 37(5):346-9. PubMed ID: 2780092
    [Abstract] [Full Text] [Related]

  • 5. [Activity of 5 fluoroquinolones on hospital Gram-negative bacilli with different sensitivities to pefloxacin].
    Aubert G, Puech C, Lucht F, Loboguerrero M, Denis M, Dorche G.
    Pathol Biol (Paris); 1989 Oct; 37(8):881-7. PubMed ID: 2515519
    [Abstract] [Full Text] [Related]

  • 6. Comparison of minimum inhibitory concentration values for fluoroquinolones against Escherichia coli causing urinary tract infection in both hospitalized patients and outpatients.
    Tayfour M, Yuce A, Yulug N.
    Saudi Med J; 2001 Oct; 22(10):848-51. PubMed ID: 11744939
    [Abstract] [Full Text] [Related]

  • 7. [Quinolone resistance of Escherichia coli strains isolated from urinary tract infections].
    Agulla A, Montes I.
    Enferm Infecc Microbiol Clin; 1994 Oct; 12(6):322. PubMed ID: 8080877
    [No Abstract] [Full Text] [Related]

  • 8. [Quinolone-resistant Escherichia coli in the health area of a 650-bed hospital].
    Fernández Fernández A, Lantero Benedito M, Gastañares Hernando MJ, Undabeitia Santisteban E, Fernández Santos F, Castaño Rodríguez A, Gil Fabra J, Martínez Castellanos F, Otero Mauricio G.
    Actas Urol Esp; 1994 Jun; 18(6):634-8. PubMed ID: 7942213
    [Abstract] [Full Text] [Related]

  • 9. In vitro activity of levofloxacin against coagulase-positive and -negative staphylococci.
    Cafiso V, Messina C, Santagati M, Campanile F, Bonfiglio G, Stefani S.
    Drugs Exp Clin Res; 2001 Jun; 27(3):107-11. PubMed ID: 11447768
    [Abstract] [Full Text] [Related]

  • 10. [In vitro susceptibility of Campylobacter jejuni and Campylobacter coli to quinolone antibiotics].
    Gür D, Hasçelik G, Akyön Y, Akalin HE, Diker S.
    Mikrobiyol Bul; 1989 Jul; 23(3):185-9. PubMed ID: 2518646
    [Abstract] [Full Text] [Related]

  • 11. [The in vitro activity of ofloxacin, pefloxacin and ciprofloxacin against various gram negative bacteria isolated from urinary tract infections].
    Tunçkanat F, Yuluğ N.
    Mikrobiyol Bul; 1988 Jul; 22(3):187-92. PubMed ID: 3252111
    [Abstract] [Full Text] [Related]

  • 12. [Antibacterial activity of norfloxacin, ofloxacin and ciprofloxacin according to resistance phenotypes to nalidixic acid and pefloxacin].
    Soussy CJ, Le Van Thoi J, Duval J.
    Pathol Biol (Paris); 1990 May; 38(5):376-84. PubMed ID: 2367152
    [Abstract] [Full Text] [Related]

  • 13. Comparative in vitro activity of ciprofloxacin, ofloxacin and pefloxacin against resistant clinical isolates.
    Periti P, Mazzei T, Nicoletti P.
    Chemioterapia; 1987 Apr; 6(2):75-8. PubMed ID: 3474081
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of plasmid conjugation by some recently synthetized 4-quinolone compounds.
    Scazzocchio F, Selan L, Oliva B, Schippa S, Cellini L, Renzini G.
    Chemioterapia; 1988 Oct; 7(5):295-7. PubMed ID: 3066516
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Evolution of fluoroquinolone resistance among Escherichia coli urinary tract isolates from a French university hospital: application of the dynamic regression model.
    Mahamat A, Lavigne JP, Fabbro-Peray P, Kinowski JM, Daurès JP, Sotto A.
    Clin Microbiol Infect; 2005 Apr; 11(4):301-6. PubMed ID: 15760427
    [Abstract] [Full Text] [Related]

  • 18. In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance.
    Gualco L, Schito AM, Schito GC, Marchese A.
    Int J Antimicrob Agents; 2007 Jun; 29(6):679-87. PubMed ID: 17363225
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparative in vitro studies with 4-quinolone antimicrobials.
    Felmingham D, O'Hare MD, Robbins MJ, Wall RA, Williams AH, Cremer AW, Ridgway GL, Grüneberg RN.
    Drugs Exp Clin Res; 1985 Jun; 11(5):317-29. PubMed ID: 2941259
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.